Abstract
Background: Long noncoding RNA (lncRNA) fetal-lethal non-coding developmental regulatory RNA (FENDRR), a newly known lncRNA, has been reported to be abnormally expressed in diverse tumors. This review is focused on clarifying the mechanism of FENDRR to regulate the biological process of tumors, affirming its value as a target for tumor therapy.
Methods: The pathophysiological mechanism of FENDRR acting on tumors has been analyzed and summarized by reviewing PubMed.
Results: The expression of lncRNA FENDRR is abnormally altered in clinical cancers, promoting the malignant transformation of a variety of tumors, including colon cancer, cervical cancer, hepatocellular carcinoma, prostate cancer, Malignant melanoma, lung cancer, osteosarcoma, breast cancer, etc. Cellular processions, including proliferation, invasion, apoptosis and migration affected by FENDRR, have been revealed.
Conclusion: Specific evidences for the involvement of LncRNA FENDRR in cancer regulatory processes suggest that FENDRR has the potential to be a biomarker or clinical therapeutic target for malignant tumors.
Keywords: Long non-coding RNA, FENDRR, cancer, biomarkers, therapeutic targets, clinical prognosis.
Current Pharmaceutical Design
Title:The Therapeutic Value and Molecular Mechanisms of lncRNA FENDRR in Human Cancer
Volume: 27 Issue: 39
Author(s): Wen Xu, Bei Wang, Yuxuan Cai, Jinlan Chen, Enqing Meng, Chong Guo, Gang Zhou*Chengfu Yuan*
Affiliation:
- College of Traditional Chinese Medicine, China Three Gorges University, Yichang 443002,China
- College of Medical Science, China Three Gorges University, Yichang 443002,China
Keywords: Long non-coding RNA, FENDRR, cancer, biomarkers, therapeutic targets, clinical prognosis.
Abstract:
Background: Long noncoding RNA (lncRNA) fetal-lethal non-coding developmental regulatory RNA (FENDRR), a newly known lncRNA, has been reported to be abnormally expressed in diverse tumors. This review is focused on clarifying the mechanism of FENDRR to regulate the biological process of tumors, affirming its value as a target for tumor therapy.
Methods: The pathophysiological mechanism of FENDRR acting on tumors has been analyzed and summarized by reviewing PubMed.
Results: The expression of lncRNA FENDRR is abnormally altered in clinical cancers, promoting the malignant transformation of a variety of tumors, including colon cancer, cervical cancer, hepatocellular carcinoma, prostate cancer, Malignant melanoma, lung cancer, osteosarcoma, breast cancer, etc. Cellular processions, including proliferation, invasion, apoptosis and migration affected by FENDRR, have been revealed.
Conclusion: Specific evidences for the involvement of LncRNA FENDRR in cancer regulatory processes suggest that FENDRR has the potential to be a biomarker or clinical therapeutic target for malignant tumors.
Export Options
About this article
Cite this article as:
Xu Wen , Wang Bei , Cai Yuxuan , Chen Jinlan, Meng Enqing, Guo Chong , Zhou Gang *, Yuan Chengfu *, The Therapeutic Value and Molecular Mechanisms of lncRNA FENDRR in Human Cancer, Current Pharmaceutical Design 2021; 27 (39) . https://dx.doi.org/10.2174/1381612827666210820094702
DOI https://dx.doi.org/10.2174/1381612827666210820094702 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HSP90 Inhibitors: Multi-Targeted Antitumor Effects and Novel Combinatorial Therapeutic Approaches in Cancer Therapy
Current Medicinal Chemistry Tubulins as Therapeutic Targets in Cancer: from Bench to Bedside
Current Pharmaceutical Design Restoration of Chemoresistance Mechanism by Novel Drug Therapies in Breast Cancer Cell Lines
Current Drug Therapy Antibacterial and Antifungal Screening of Novel α-amino Acid Conjugated Bile Acid Derivatives
Current Bioactive Compounds Design and Synthesis of 3,4-diarylpyrrole Analogues as Potent Topoisomerase Inhibitors
Medicinal Chemistry Targeting P-glycoprotein for Effective Oral Anti-Cancer Chemotherapeutics
Current Cancer Drug Targets Gene Directed Enzyme Prodrug Therapy for Ovarian Cancer: Could GDEPT Become a Promising Treatment Against Ovarian Cancer?
Anti-Cancer Agents in Medicinal Chemistry Platinum(II) and Palladium(II) Complex Compounds as Anti-cancer Drugs. Methods of Cytotoxicity Determination
Current Pharmaceutical Analysis Regulation of Hypoxia-inducible Factor-1α and Vascular Endothelial Growth Factor Signaling by Plant Flavonoids
Mini-Reviews in Medicinal Chemistry Novel Concepts in the Development of Platinum Antitumour Drugs: An Update
Medicinal Chemistry Reviews - Online (Discontinued) Isovitexin Inhibits Stemness and Induces Apoptosis in Hepatocellular Carcinoma SK-Hep-1 Spheroids by Upregulating miR-34a Expression
Anti-Cancer Agents in Medicinal Chemistry Regioselective Synthesis of Biologically Important Scaffold Spiro [Indole- Perimidines]: An Antitumor Agents
Letters in Organic Chemistry Ribosome-inactivating Proteins from Root Tubers and Seeds of Trichosan-thes kirilowii and Other Trichosanthes Species
Protein & Peptide Letters Shear-Wave and Strain Elastography: A Comparative Review on Principles, Basic Techniques and Applications.
Current Medical Imaging The Clinical Perspective on Value of 3D, Thin Slice T2-Weighted Images in 3T Pelvic MRI for Tumors
Current Medical Imaging Circulating Biomarkers for Tumor Angiogenesis: Where Are We?
Current Medicinal Chemistry Heat Shock Protein (HSP) Drug Discovery and Development: Targeting Heat Shock Proteins in Disease
Current Topics in Medicinal Chemistry Meet Our Editorial Board Member
Current Drug Delivery γ-Hydroxybutenolide Containing Marine Natural Products and Their Synthesis: A Review
Current Organic Chemistry Calcium Carbonate Microparticles as Carriers of <sup>224</sup>Ra: Impact of Specific Activity in Mice with Intraperitoneal Ovarian Cancer
Current Radiopharmaceuticals